aDiane M. Thiboutot, MD; bLeon Kircik, MD; cAmy McMichael, MD; dFran E. Cook-Bolden, MD; eStephen K. Tyring, MD, PhD; fDavid R. Berk, MD; fJoan-En Chang-Lin, PhD; fVince Lin, PhD; fAlexandre
Iris Westra, MSc, MD; HTH Pham, MSC, MD; Frank B. Niessen, MD, PhD Department of Plastic, Reconstructive and Hand Surgery, VU University Medical Centre, Amsterdam, The Netherlands Disclosure: The authors
aPeter W. Hashim, MD, MHS; bPhilip Friedlander, MD, PhD; aGary Goldenberg, MD aDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; bDivision of Hematology and
Christopher Rizk, MD; Holly Monroe, MD; Ida Orengo, MD; Theodore Rosen, MD Department of Dermatology, Baylor College of Medicine, Houston, Texas Disclosure: The authors report no relevant conflicts of interest
a)Stefano Veraldi, Md; b)Giuseppe Micali, Md; c)Enzo Berardesca, Md; b)Federica Dall’oglio, Md; c)Jo Linda Sinagra, Md; aElena Guanziroli, Md aDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, I.R.C.C.S.
Vic A. Narurkar, MD Bay Area Laser Institute, San Francisco, California Abstract Objective: To evaluate a hydrolyzed roe cream in the reduction of facial erythema following a chemical peel treatment.